Clinical trial
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at…
NCT00364351 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00364351 |
|---|---|
| Title | Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy |
| Official title | A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Vandetanib, Erlotinib |
| Enrollment | 1,574 |
| Start date | Aug 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Nov 1, 2016 |
| First posted | Aug 15, 2006 |
| Last update posted | Jan 25, 2018 |
| Countries | Argentina, Australia, Brazil, Canada, China, Denmark, France, Germany, Hong Kong, India, Indonesia, Italy and 10 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: